---
title: "Oculis Holding AG (OCS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/OCS.US.md"
symbol: "OCS.US"
name: "Oculis Holding AG"
industry: "Pharmaceuticals"
---

# Oculis Holding AG (OCS.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [oculis.com](https://oculis.com) |

## Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for th...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: D (0.67)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 132 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.97% |  |
| Net Profit YoY | -54.28% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 10.05 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.65B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 938707.68 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -92.19% | E |
| Profit Margin | -13160.30% | E |
| Gross Margin | -5709.47% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.97% | D |
| Net Profit YoY | -54.28% | D |
| Total Assets YoY | 40.86% | A |
| Net Assets YoY | 44.57% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.76% | D |
| OCF YoY | -5.97% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 22.19% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Oculis Holding AG",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-92.19%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-13160.30%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-5709.47%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.97%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-54.28%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "40.86%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "44.57%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.76%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-5.97%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "22.19%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.32 | 193/257 | - | - | - |
| PB | 10.05 | 173/257 | 10.01 | 6.25 | 5.29 |
| PS (TTM) | 1753.22 | 153/257 | 1276.86 | 1191.68 | 1076.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 70% |
| Overweight | 3 | 30% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 29.28 |
| Highest Target | 57.81 |
| Lowest Target | 30.33 |

## References

- [Company Overview](https://longbridge.com/en/quote/OCS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/OCS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/OCS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.